Selective COX 2 Inhibitors

Parecoxib, Rofecoxib, Celecoxib, Valdecoxib
They do not depress TXA 2 production by platelets (COXI dependent), but reduce PGI2 production by vascular endothelium (COX2 dependant)
Only in patients at high risk of peptic ulcer, perforation or bleeds
They should be given in lowest dose for shortest period of time
Avoided in patients of cardiovascular risk factors